Greenwood: Future BIO Global Efforts Include International Relations
This article was originally published in The Pink Sheet Daily
BIO joins forces with other national biotech associations to lobby the World Health Organization on intellectual property, innovation and public health.
You may also be interested in...
Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Exec discusses the firm’s pulmonary arterial hypertension drug Tracleer and other endothelin receptor antagonists in Actelion’s pipeline.